Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Smith CIE, Wullimann D, Vesterbacka J, Lindgren G, Blixt L, Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini D, Norlin AC, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K, Chen MS, Buggert M, Ljunggren HG, Ljungman P, Aleman S; COVAXID-collaborator group (shown separately).
Bergman P, et al. Among authors: wahren borgstrom e.
EBioMedicine. 2021 Dec;74:103705. doi: 10.1016/j.ebiom.2021.103705. Epub 2021 Nov 30.
EBioMedicine. 2021.
PMID: 34861491
Free PMC article.
Clinical Trial.